Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT02061787
Recruiting Observational

the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension

NCT02061787 · tracked via the Priya Life Science China tracker
Sponsor
Chinese Pulmonary Vascular Disease Research Group
Phase
Observational
Started
2010-09
Last updated
2024-09-19

Condition(s) studied

Pulmonary HypertensionChronic Thromboembolic Pulmonary HypertensionPulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)

Investigational drug(s) / intervention(s)

balloon pulmonary angioplasty

balloon pulmonary angioplasty: patients with chronic thromboembolic pulmonary hypertension who underwent balloon pulmonary angioplasty

Study summary

cardiopulmonary exercise test evaluate patients with pulmonary hypertension before and after medical or balloon pulmonary angioplasty treatment

Eligibility

Sex
ALL
Min age
5 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion Criteria: * pulmonary arterial hypertension;( WHO1) * chronic thromboembolic pulmonary hypertension; * pulmonary arterial hypertension due to other cause; Exclusion Criteria: * massive hemoptysis; * unable to accomplish cardiopulmonary exercise testing due to neuromuscular disorders; * recent recurrent syncope; * pulmonary hypertension due to hypoxia; * pulmonary hypertension due to left heart diseases.

Primary outcome measure(s)

  • all cause mortality — 5 years
    all cause mortality
  • mean pulmonary arterial pressure after treatment — 5 years
    the mean pulmonary arterial pressure of patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty treatment
  • achievement of low risk — 5 years
    patients with chronic thromboembolic pulmonary hypertension achievement of low risk after balloon pulmonary angioplasty

Trial sites (1)

FacilityCityRegionStatus
center of pulmonary vascular disease, Fuwai hospital Beijing China Recruiting

More Chinese Pulmonary Vascular Disease Research Group trials in China

PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension Recruiting
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension Recruiting
Safety and Efficacy of Balloon Pulmonary Angioplasty in China Recruiting
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement Recruiting
Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension Recruiting

Other trials for the same condition

Clinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure Active, not recruiting
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study Recruiting
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension Recruiting
Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study Recruiting
Safety and Efficacy of Balloon Pulmonary Angioplasty in China Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02061787 on ClinicalTrials.gov ↗ ← All trials in China